Avoiding drug interactions.
作者信息
Generali J
出版信息
Am Fam Physician. 2000 Mar 15;61(6):1628, 1630, 1637.
PMID:10750872
Abstract
摘要
相似文献
1
Avoiding drug interactions.
Am Fam Physician. 2000 Mar 15;61(6):1628, 1630, 1637.
2
FDA drug information that never reaches clinicians.
N Engl J Med. 2010 Feb 11;362(6):562; author reply 563.
3
"Black box" warning: wake-up call or overreaction?
J Allergy Clin Immunol. 2006 Jan;117(1):26-9. doi: 10.1016/j.jaci.2005.11.006.
4
Primum non nocere and "black box" warnings.
J Allergy Clin Immunol. 2006 Jan;117(1):30-1. doi: 10.1016/j.jaci.2005.09.030. Epub 2005 Dec 2.
5
Black box warnings-implications in practice.
Geriatr Nurs. 2008 Nov-Dec;29(6):402-9. doi: 10.1016/j.gerinurse.2008.09.005.
6
FDA cracks down on labeling, initiates trial result reporting.
Nat Biotechnol. 2008 Nov;26(11):1203-4. doi: 10.1038/nbt1108-1203.
7
Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
Food Drug Law J. 2007;62(4):653-94.
8
Institute of Medicine's new drug safety report: implications for Canada.
CMAJ. 2006 Dec 5;175(12):1515-6. doi: 10.1503/cmaj.061437.
9
Why drugs get pulled off the market.
FDA Consum. 2002 Jan-Feb;36(1):11-7.
10
"Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
J Allergy Clin Immunol. 2006 Jan;117(1):34-9. doi: 10.1016/j.jaci.2005.10.031.
Zotero 插件